We recently published 10 Stocks Hit by Painful Plunge. Novo Nordisk A/S (NYSE:NVO) is one of the best-performing stocks on ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

That pundit was HSBC's Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning. Image source: . Kumar ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...

Novo Nordisk has struggled to adapt to very high demand and a market where celebrities are more influential than doctors.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0815 GMT – Sanofi’s higher costs overshadow an upgrade to its ...

David Ellison has finally sealed his $8bn takeover of Paramount, but only after a year of boardroom battles and bloodletting ...

Pomerantz LLP is investigating claims on behalf of investors of  Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).  Such investors are advised to contact Danielle Peyton ...

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Shares of telehealth company Hims & Hers Health are up Thursday afternoon. The rally comes amid significant headwinds for major pharmaceutical companies in the lucrative weight-loss drug market.